Health Canada approved Imbruvica (ibrutinib) as an oral, once-daily, single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia. This is the fourth Canadian approval for Imbruvica, which is now approved for use in all lines of CLL therapy.
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
